News
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
Calgary, Alberta–(Newsfile Corp. – February 15, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to report the proxy tabulation (“Tabulation“) from Odyssey...
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
Calgary, Alberta–(Newsfile Corp. – February 8, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”) is pleased to provide a corporate update on the operations of the...